New Delhi, March 20 -- With the patent expirations for GLP-1 drugs, used for treating type 2 diabetes and obesity, major Pharma companies in India are lining up cheaper generic alternatives.

These alternatives are likely to be priced at a significantly lower price as compared to the current costs. Acording to the National Family Health Survey (NFHS-5, 2019-21) nearly 24 % of women and 23% of men are overweight or obese, this has resulted in the increase in popularity of GLP-1 drugs.

However, top experts caution that it is critical to ensure strict pharmaco vigilance for these drugs.

Dr V Mohan, renowned diabetologist and Chairman of Dr Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation said, "Strict pharmaco v...